Covid related data and resources

Resources and data are added frequently. Please keep checking back for updates. (updated 2-20-22)


December 16, 2021 "SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study"

"Vaccination with mRNA-1273 was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population, primarily driven by an increased risk among individuals aged 12-39 years..."

October 29, 2021 "Community Transmission and Viral Load Kinetics of the SARS Cov-2 Delta Variant in Vaccinated and Unvaccinated Individuals in the UK"

"Vaccination reduces the risk of delta variant infection and accelerates viral clearance. Nonetheless, fully vaccinated individuals with breakthrough infections have peak viral load similar to unvaccinated cases and can efficiently transmit infection in household settings, including to fully vaccinated contacts. Host–virus interactions early in infection may shape the entire viral trajectory." (emphasis added)

October 24, 2021 "The Obvious Wins Again: Natural Immunity Superior to Vaccine Immunity"

NOTE: This is not a study. However, the PDF with the article has volumes of footnotes to studies, etc, so it is included here as a well-researched article and document.


October 17, 2021 "102 Research Studies Affirm Naturally Acquired Immunity to Covid-19: Documented, Linked, and Quoted"

NOTE: This is not a study; however this article has direct links to the 102 studies mentioned.

September, 2021 "Efficacy of vaccination against severe Covid-19 in relation to Delta variant and time since second dose: the REACT-SCOT case control study"

"Although there is considerable uncertainty attached to any extrapolation into the future, these results suggest that the rapid early waning of efficacy against hospitalised COVID-19 after the second dose tapers off within a few months. This weakens the rationale for policies based on delivering booster doses to the entire population, rather than to vulnerable individuals for focused protection." (emphasis added)

September 13, 2021 "Considerations in boosting COVID-19 vaccine immune responses"

"Current evidence does not, therefore, appear to show a need for boosting in the general population, in which efficacy against severe disease remains high." (emphasis added)

September 8, 2021 "SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis"

"Post-vaccination CAE rate was highest in young boys aged 12-15 following dose two. For boys 12-17 without medical comorbidities, the likelihood of post vaccination dose two CAE is 162.2 and 94.0/million respectively. This incidence exceeds their expected 120-day COVID-19 hospitalization rate at both moderate (August 21, 2021 rates) and high COVID-19 hospitalization incidence. Further research into the severity and long-term sequelae of post-vaccination CAE is warranted. Quantification of the benefits of the second vaccination dose and vaccination in addition to natural immunity in this demographic may be indicated to minimize harm." (emphasis added)

PDF here includes graphs of data:

August 19, 2021 "Covid-19: Fully vaccinated people can carry as much delta virus as unvaccinated people, data indicate"

"Commenting on the findings, the University of East Anglia’s Paul Hunter noted, “There is now quite a lot of evidence that all vaccines are much better at reducing the risk of severe disease than they are at reducing the risk from infection. We now know that vaccination will not stop infection and transmission, [but it does] reduce the risk. The main value of immunisation is in reducing the risk of severe disease and death.” (emphasis added)

August 10, 2021 "Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam"

"Breakthrough Delta variant infections are associated with high viral loads, prolonged PCR positivity, and low levels of vaccine-induced neutralizing antibodies, explaining the transmission between the vaccinated people."

June 19, 2021 "Necessity of COVID-19 vaccination in previously infected individuals"

"Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before."

June 17, 2021 "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons"

"Our preliminary analysis uses participant-reported data and has limited information on other potential risk factors for adverse pregnancy and neonatal outcomes. The VAERS is subject to the limitations of passive surveillance.12 Despite EUA mandatory reporting requirements and CDC guidance on VAERS reporting, there is probably substantial underreporting of pregnancy- and neonatal-specific adverse events. We also do not know the total number of Covid-19 vaccine doses administered to pregnant persons, which further limits our ability to estimate rates of reported adverse events from VAERS data. Among pregnancy-specific conditions reported to the VAERS after Covid-19 vaccination, miscarriage was the most common. This is similar to what was observed during the influenza A (H1N1) pandemic in 2009 after the introduction of the 2009 H1N1 inactivated influenza vaccine, where miscarriage was the most common adverse event reported by pregnant persons who received that vaccine." (emphasis added)

June 15, 2021 "Neurological and other Adverse events in Clinical Trials"

February 12, 2021 "Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies"

"Given past data on multiple SARS-CoV-1 and MERS-CoV vaccine efforts have failed due to ADE in animal models (75, 81), it is reasonable to hypothesize a similar ADE risk for SARS-CoV-2 antibodies and vaccines. ADE risks may be associated with antibody level (which can wane over time after vaccination) and also if the antibodies are derived from prior exposures to other coronaviruses. In addition, ADE with mast cells likely plays a role in MIS-C for infants and possibly older MIS-C and MIS-A patients. While expanded trophism of SARS-CoV-2 represents a possible ADE risk in the subset of COVID-19 patients with disease progression beyond the mild disease stage." (emphasis added)

Natural Immunity

NOTE: Many of the studies listed below can be found referenced at this website, along with over 100 other studies.

January 19, 2022 "COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021"

"As the Delta variant prevalence increased to >95% (97% in Region 9 and 98% in Region 2 on August 1), rates increased more rapidly among the vaccinated group with no previous COVID-19 diagnosis than among both the vaccinated and unvaccinated groups with a previous COVID-19 diagnosis...During October 3–16, compared with hospitalization rates among unvaccinated persons without a previous COVID-19 diagnosis, hospitalization rates were 19.8-fold lower among vaccinated persons without a previous COVID-19 diagnosis, 55.3-fold lower among unvaccinated persons with a previous COVID-19 diagnosis, and 57.5-fold lower among vaccinated persons with a previous COVID-19 diagnosis." (emphasis added)

December 3, 2021 "Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study"

"SARS-CoV-2 infection is highly protective against reinfection with Delta. Immunity from prior infection lasts at least 13 months. Countries facing vaccine shortages should consider delaying vaccinations for previously infected patients to increase access."

September 27, 2021 "Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans"

“Assessed the persistence of serum antibodies following WT SARS-CoV-2 infection at 8 and 13 months after diagnosis in 367 individuals…found that NAb against the WT virus persisted in 89% and S-IgG in 97% of subjects for at least 13 months after infection. (emphasis added)

August 29, 2021 "A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection"

"The protective effect of prior SARS-CoV-2 infection on re-infection is high and similar to the protective effect of vaccination. More research is needed to characterize the duration of protection and the impact of different SARS-CoV-2 variants." (emphasis added)

August 25, 2021 "Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections"

“...SARS-CoV-2-naïve vaccines had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected...The increased risk was significant (P<0.001) for symptomatic disease as well. When allowing the infection to occur at any time before vaccination (from March 2020 to February 2021), evidence of waning natural immunity was demonstrated, though SARS-CoV-2 naïve vaccines had a 5.96-fold (95%) increased risk for breakthrough infection and a 7.13-fold (95% CI, 5.51 to 9.21) increased risk for symptomatic disease. SARS-CoV-2-naïve vaccines were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected” (emphases added)

July 29, 2021 "Antibody Evolution after SARS-CoV-2 mRNA Vaccination"

"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B-cell responses that continue to evolve for at least one year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern...We conclude that memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination." (emphasis added)

June 4, 2021 "SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity"

"The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8+ T-cell responses. Overall, the majority of patients had robust adaptive immune responses, regardless of their disease severity."

May 24, 2021 "SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans"

"Overall, our results indicate that mild infection with SARS-CoV-2 induces robust antigen-specific, long-lived humoral immune memory in humans."

May 18, 2021 "Quantifying the risk of SARS‐CoV‐2 reinfection over time"

Eleven large cohort studies were identified that estimated the risk of SARS‐CoV‐2 reinfection over time, including three that enrolled healthcare workers and two that enrolled residents and staff of elderly care homes. Across studies, the total number of PCR‐positive or antibody‐positive participants at baseline was 615,777, and the maximum duration of follow‐up was more than 10 months in three studies. Reinfection was an uncommon event (absolute rate 0%–1.1%), with no study reporting an increase in the risk of reinfection over time. (emphasis added)

March 19, 2021 "Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection"

"We also demonstrate the size and quality of the memory T-cell pool of COVID-19 patients are larger and better than those of close contacts. However, the proliferation capacity, size and quality of T-cell responses in close contacts are readily distinguishable from healthy donors, suggesting close contacts are able to gain T-cell immunity against SARS-CoV-2 despite lacking a detectable infection. Additionally, asymptomatic and symptomatic COVID-19 patients contain similar levels of SARS-CoV-2-specific T-cell memory. Overall, this study demonstrates the versatility and potential of memory T cells from COVID-19 patients and close contacts, which may be important for host protection." (emphasis added)

March 1, 2021 "Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection"

"...asymptomatic SARS-CoV-2–infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response." (emphasis added)

February 13, 2021 "SARS-CoV-2 re-infection risk in Austria"

"We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies." (emphasis added)

February 5, 2021 "Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection"

"Substantial immune memory is generated after COVID-19, involving all four major types of immune memory. About 95% of subjects retained immune memory at ~6 months after infection. Circulating antibody titers were not predictive of T cell memory. Thus, simple serological tests for SARS-CoV-2 antibodies do not reflect the richness and durability of immune memory to SARS-CoV-2. This work expands our understanding of immune memory in humans. These results have implications for protective immunity against SARS-CoV-2 and recurrent COVID-19." (emphasis added)

July 15, 2020 "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls"

"In all of these individuals, we found CD4 and CD8 T cells that recognized multiple regions of the N protein…showed that patients (n = 23) who recovered from SARS possess long-lasting memory T cells that are reactive to the N protein of SARS-CoV 17 years after the outbreak of SARS in 2003; these T cells displayed robust cross-reactivity to the N protein of SARS-CoV-2.” (emphasis added)



January 15, 2022 "Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching"

"Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates."

September 9, 2021 "Ivermectin for COVID-19: real-time meta analysis of 63 studies"

"Ivermectin is an effective treatment for COVID-19. Treatment is more effective when used early. Meta analysis using the most serious outcome reported shows 69% [54‑79%] and 86% [75‑92%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis and restriction to peer-reviewed studies or Randomized Controlled Trials. Statistically significant improvements are seen for mortality, hospitalization, recovery, cases, and viral clearance. 29 studies show statistically significant improvements in isolation. The consistency of positive results across a wide variety of heterogeneous studies is remarkable, with 92% of the 63 studies reporting positive effects." (emphases added)

September, 2021 "Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19"

"Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments." (emphasis added)

August 18, 2021 "Bayesian Meta Analysis of Ivermectin Effectiveness in Treating Covid-19 Disease"

"We show that there is strong evidence to support a causal link between ivermectin, Covid-19 severity and mortality...for patients with severe Covid-19, the mean probability of death without ivermectin treatment is 22.9%, whilst with the application of ivermectin treatment it is 11.7%." (emphases added)

August 5, 2021 "Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers"

"Of 3892 employees, 3532 (90.8%) participated in the study. The ivermectin uptake was 62.5% and 5.3% for two doses and single dose, respectively. Participants who took ivermectin prophylaxis had a lower risk of getting symptoms suggestive of SARS-CoV-2 infection (6% vs 15%). HCWs who had taken two doses of oral ivermectin had a significantly lower risk of contracting COVID-19 infection during the following month (ARR 0.17; 95% CI, 0.12-0.23). Females had a lower risk of contracting COVID-19 than males (ARR 0.70; 95% CI, 0.52-0.93). The absolute risk reduction of SARS-CoV-2 infection was 9.7%. Only 1.8% of the participants reported adverse events, which were mild and self-limiting." (emphases added)

June, 2021 "Overseas Refugee Health Guidance"

Scroll down to Summary of Recommendations and note that Ivermectin is a recommended part of presumptive therapy.

January 15, 2021 "Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19"

(Summary of controlled trials in prophylaxis and treatment begins on p.20 of the PDF.)

Video summarizing the data:

December, 2020 "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness"

"There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19." (emphasis added)


January 19, 2022 "A Partial List of the Myriad Abuses That Facemasks Inflict on Our Children"

NOTE: This is not a study

September 3, 2021 "Analysis of the Effects of COVID-19 Mask Mandates on Hospital Resource Consumption and Mortality at the County Level"

"There was no reduction in per-population daily mortality, hospital bed, ICU bed, or ventilator occupancy of COVID-19-positive patients attributable to the implementation of a mask-wearing mandate."

March, 2021 "Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers"

"A total of 3030 participants were randomly assigned to the recommendation to wear masks, and 2994 were assigned to control; 4862 completed the study. Infection with SARS-CoV-2 occurred in 42 participants recommended masks (1.8%) and 53 control participants (2.1%). The between-group difference was −0.3 percentage point (95% CI, −1.2 to 0.4 percentage point; P = 0.38) (odds ratio, 0.82 [CI, 0.54 to 1.23]; P = 0.33). Multiple imputation accounting for loss to follow-up yielded similar results. Although the difference observed was not statistically significant, the 95% CIs are compatible with a 46% reduction to a 23% increase in infection."

January 7, 2021 "Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020"

"Norwegian schools were closed during the first SARS-CoV-2 wave in spring 2020. After re-opening, all schools implemented infection prevention and control (IPC) measures based on national guidelines. These included strengthened hygiene measures, physical distancing and a clear message to stay home if symptomatic, even with mild symptoms [17]. Use of face masks is not recommended in schools in Norway. We found that with the IPC measures implemented there is low to no transmission from SARS-CoV-2–infected children in schools." (emphasis added)

An Interesting Case

June 30, 2021 "Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children"

"We measured means (SDs) between 13 120 (384) and 13 910 (374) ppm of carbon dioxide in inhaled air under surgical and filtering facepiece 2 (FFP2) masks, which is higher than what is already deemed unacceptable by the German Federal Environmental Office by a factor of 6. This was a value reached after 3 minutes of measurement. Children under normal conditions in schools wear such masks for a mean of 270 (interquartile range, 120-390) minutes."

Original study:

Retraction of the study:

Original study author's response to the retraction:

Mandates, exemptions

Current Lawsuits

February 10, 2022 Lawsuit filed against Chris Reykdal and OSPI in WA state:

September 10, 2021 Lawsuit filed against Gov. Inslee, in Franklin Co.

September 10, 2021 Lawsuit filed against Gov. Inslee, in Walla Walla Co.

Legal Organizations

Silent Majority Foundation

Liberty Counsel

Liberty Counsel Action

March for Freedom Washington

America's Frontline Doctors

Informed Consent Action Network

Liberty Institute

Pacific Justice Institute

Advocates for Faith and Freedom

Alliance Defending Freedom

National Legal Foundation

Thomas More Law Center

Thomas More Society

Christian Legal Society

American Center for Law and Justice

Center for Law and Religious Freedom

Christian Attorneys of America

Christian Law Association

National Association of Christian Lawmakers

Pacific Legal Foundation

One Washington

Other Data

January, 2022 "A Literature Review and Meta-Analysis of the Effects of Lockdowns on COVID-19 Mortality"

"While this meta-analysis concludes that lockdowns have had little to no public health effects, they have imposed enormous economic and social costs where they have been adopted. In consequence, lockdown policies are ill-founded and should be rejected as a pandemic policy instrument."

October 22, 2021 (article) "The Politicization of Immunology"

Among other excellent points, this immunologist discusses "four reasons why immunity acquired by infection is different than immunity acquired by vaccination."

October 17, 2021 (article) "Pilots in Flight at Higher Risk of Death from Myocarditis After mRNA COVID Shots Says Army Surgeon"

AFFIDAVIT from article

September 18, 2021 (article) "FDA Panel Votes Against Pfizer’s COVID Booster for Everyone, Recommends It for People 65 and Older"

September 17, 2021 "Vaccines and Related Biological Products Advisory Committee Meeting" (briefing document)

DATA from the footnotes of the above document:

(footnote 4) "Covid-19 Breakthrough Infections in Vaccinated Health Care Workers"

(footnote 5) "Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study"

"Although there is considerable uncertainty attached to any extrapolation into the future, these results suggest that the rapid early waning of efficacy against hospitalised COVID-19 after the second dose tapers off within a few months. This weakens the rationale for policies based on delivering booster doses to the entire population, rather than to vulnerable individuals for focused protection." (emphasis added)

2021 "Adjudicating Reasons for Hospitalization Shows That Severe Illness From COVID-19 in Children Is Rare" (from Hospital Pediatrics, an official journal of the American Academy of Pediatrics)

From this peer-reviewed study: "Taken together, these studies underscore the importance of clearly distinguishing between children hospitalized with SARS-CoV-2 found on universal testing versus those hospitalized for COVID-19 disease. Both demonstrate that reported hospitalization rates greatly overestimate the true burden of COVID-19 disease in children." (emphasis added)

September 13, 2021 "The COVID-19 Hospitalization Metric in the Pre- and Post-vaccination Eras as a Measure of Pandemic Severity: A Retrospective, Nationwide Cohort Study"

"The proportion with moderate-to-severe disease prior to widespread vaccine availability was 64.0% (95% CI, 63.1-64.9%) versus 52.0% in the later period (95% CI, 50.9-53.2%), p-value for non-constant effect, <0.001. Disease severity in the vaccine era among hospitalized patients was lower among both unvaccinated (55.0%, 95% CI, 53.7-56.4%) and vaccinated patients (42.6%, 95% CI, 40.6-44.8%)...The proportion of hospitalizations that are due to severe COVID-19 has changed with vaccine availability, thus, increasing proportions of mild and asymptomatic cases are included in hospitalization reporting metrics. The addition of simple measures of disease severity to the case definition of a SARS-CoV-2 hospitalization is a straightforward and objective change that should improve the value of the metric for tracking SARS-CoV-2 disease burden." (emphasis added)

August 3, 2021 "Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients"

"Significant findings favoring influenza vaccination mitigating the risks of sepsis, stroke, deep vein thrombosis (DVT), emergency department (ED) & Intensive Care Unit (ICU) admissions suggest a potential protective effect that could benefit populations without readily available access to SARS-CoV-2 vaccination."

Covid pediatric hospitalizations (Click link, then select specific state for state data.)

Protests and Events